Comparison of camrelizumab, pembrolizumab, tislelizumab, and sintilimab as first-line treatment in patients with non-small cell lung cancer: a retrospective study
Camrelizumab, pembrolizumab, tislelizumab, and sintilimab possess similar efficacy as first-line treatment options for patients with advanced NSCLC in Chinese clinical practice. Any grade or grade ≥3 irAEs are comparable between the four PD-1 inhibitors.
Authors
- Xiaoqi Yan
- Fei Wu (ORCID: https://orcid.org/0000-0001-5837-0926)
- Guoren Zhou (ORCID: https://orcid.org/0000-0001-5344-8480)
- Yizong Wang (ORCID: https://orcid.org/0000-0003-4492-374X)
- Shaorong Yu
- Jiannan Shen
Institutions
- Jiangsu Cancer Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal of Thoracic Disease
- Published
- 2025-02-01
- DOI
- https://doi.org/10.21037/jtd-24-1495
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- National Natural Science Foundation of China
- Government of Jiangsu Province